Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Ulahannan on the PRODIGE Trial in Pancreatic Cancer

Susanna Ulahannan, MD
Published: Tuesday, Jul 10, 2018



Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.

The phase III GI PRODIGE 24/CCTG PA.6 trial was presented at the 2018 ASCO Annual Meeting and examined the use of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. The trial was conducted in France and Canada.

The importance of a study like this cannot be understated, as the overall survival (OS) in pancreatic cancer, even resectable pancreatic cancer, is poor, says Ulahannan. OS has typically hovered around 24 months to 28 months with the previous standard of care of gemcitabine and capecitabine.

The modified FOLFIRINOX regimen had an OS of 54.5 months, says Ulahannan, representing a 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P = .003). The median disease-free survival was 8.8 months longer with mFOLFIRINOX than with gemcitabine.


Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.

The phase III GI PRODIGE 24/CCTG PA.6 trial was presented at the 2018 ASCO Annual Meeting and examined the use of adjuvant mFOLFIRINOX versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma. The trial was conducted in France and Canada.

The importance of a study like this cannot be understated, as the overall survival (OS) in pancreatic cancer, even resectable pancreatic cancer, is poor, says Ulahannan. OS has typically hovered around 24 months to 28 months with the previous standard of care of gemcitabine and capecitabine.

The modified FOLFIRINOX regimen had an OS of 54.5 months, says Ulahannan, representing a 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P = .003). The median disease-free survival was 8.8 months longer with mFOLFIRINOX than with gemcitabine.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Integrating Novel Targeted Treatment Strategies to Advance Pancreatic Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x